4.6 Review

Co-Infection of the Epstein-Barr Virus and the Kaposi Sarcoma-Associated Herpesvirus

期刊

VIRUSES-BASEL
卷 14, 期 12, 页码 -

出版社

MDPI
DOI: 10.3390/v14122709

关键词

natural killer cells; cytotoxic lymphocytes; T cells; latent and lytic infection; B cell lymphomas; Kaposi sarcoma; humanized mice

类别

资金

  1. Cancer Research Switzerland [KFS-4962-02-2020]
  2. Sobek Foundation
  3. Swiss Vaccine Research Institute
  4. Roche
  5. Swiss MS Society [2021-09]
  6. Swiss National Science Foundation [310030_204470/1, 310030L_197952/1, 323630_199389, CRSII5_180323]
  7. CRPP-ImmunoCure and HMZ ImmunoTargET of the University of Zurich
  8. Novartis
  9. Forschungskredit Universitaet Zuerich [K-41301-08-01]

向作者/读者索取更多资源

This article discusses the importance of the interaction and coexistence of EBV and KSHV, as well as their relationship with immune control. A better understanding of this immune control could potentially help in future vaccination against EBV and KSHV.
The two human tumor viruses, Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV), have been mostly studied in isolation. Recent studies suggest that co-infection with both viruses as observed in one of their associated malignancies, namely primary effusion lymphoma (PEL), might also be required for KSHV persistence. In this review, we discuss how EBV and KSHV might support each other for persistence and lymphomagenesis. Moreover, we summarize what is known about their innate and adaptive immune control which both seem to be required to ensure asymptomatic persistent co-infection with these two human tumor viruses. A better understanding of this immune control might allow us to prepare for vaccination against EBV and KSHV in the future.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据